The clinical relevance of these biomarkers has been extensively validated: CXCL14 expression in tumor stroma has been confirmed as an independent survival marker, with fibroblast-derived CXCL14 promoting epithelial-to-mesenchymal transition and metastasis through ACKR2-dependent mechanisms [29, 40, 41]. This evidence concerns the gene ACKR2 and neoplasm.